Momestasone furoate lipidosome cream

Abstract

The invention relates to a lipidosome medical composition which uses momestasone furoate as an active component, and a cyst diameter of lipidosome is smaller than 800nm. The composition comprises 0.025 percent to 0.2 percent of momestasone furoate as the active component, 0.5 percent to 6 percent of phospholipid, 0 percent to 1 percent of lipophilic additive, 0.01 percent to 1 percent of antioxidant which is used for preserving the medical composition, a pH buffering agent which is used for retaining a pH value from 5 to 7.5, 3 percent to 15 percent of humectant, 20 percent to 30 percent of oil phrase component, 0.01 percent to 0.1 percent of antimicrobial preservative and the balanced of water. The momestasone furoate lipidosome cream is used for treating skin diseases of human beings oranimals.

Description

field of invention [0001] The invention relates to a liposome preparation, in particular to a cream containing mometasone furoate liposome. Background technique [0002] Mometasone furoate (mometasone furoate, CAS: 83919-23-7), its molecular formula is as follows: [0003] [0004] The trade name of mometasone furoate cream is Elocon, which was first developed and listed by Schering Corporation in 1988. At present, there is only one specification of 0.1%, and the manual of Elocon cream (http: / / www.fda.gov / cder / pediatric / labels / Mometasone%20Cream.pdf) discloses that its main component is: mometasone furoate 0.1 %; Excipients: hexylene glycol (hexylene glycol), phosphoric acid, propylene glycol monostearate (55% monoester), stearyl alcohol, ceteareth-20 (ceteareth-20), titanium dioxide, Aluminum octenyl succinate starch, white wax, white petrolatum, purified water, but the drug also has side effects of general skin glucocorticoid preparations, such as inhibition of the HP...

AI Technical Summary

Problems solved by technology

[0006] Chinese patent application CN200380107482.0 discloses a liposome preparation containing water-soluble glucocorticoids, but the technical scheme of the application only discloses that it is suitable for water-soluble glucocorticoids such as dexamethasone sodium phosphate, etc.

[0007] Chinese patent application CN200580035942.2 discloses a liposome composition of glucocorticoids and glucocorticoid derivatives, yet the technical scheme of the application only discloses the liposome composition applicable to amphiphilic weakly basic glucocorticoids such as methylprednisolone succinate Sodium acid, and pointed out in this application specification that hydrophobic glucocorticoid (GC) is difficult to pack into liposome (instruction page 6)

[0009] Chinese patent ZL 01812895.5 discloses a liposome preparation containing the hydrophobic glucocorticoid clobetasol propionate. In the technical scheme disclosed by the invention, it is preferably made into a gel, but in the technical scheme disclosed in this patent , the ratio of the amount of cholesterol and phospholipids used as lipophilic additives is only 1:1~1:3, and the diameter of liposome vesicles is as high as 2000-5000nm. The liposome vesicle diameter of the liposome is relatively large, which affects the penetration and absorption of the drug, and cannot give full play to the advantages of liposome administration for external use on the skin

Images